Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

By

Bret Jensen

 | Feb 16, 2018 | 11:30 AM EST
I continue to believe that 2018 will be a year of inflection and much more volatile for equity holders than the placid 2017.
RMPIA
By

Bret Jensen

 | Feb 14, 2018 | 11:37 AM EST
I continue to deploy some of the 'dry powder' into the market after its recent hiccup.
By

Bret Jensen

 | Feb 12, 2018 | 1:44 PM EST
My personal view is the market is getting used to a sustainable economic uptick and the accompanying rise in interest rates.
By

Bret Jensen

 | Feb 12, 2018 | 12:30 PM EST
My personal view is the market is getting used to a sustainable economic uptick and the accompanying rise in interest rates.
By

Bret Jensen

 | Feb 10, 2018 | 12:00 PM EST
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
By

Bret Jensen

 | Feb 9, 2018 | 7:00 AM EST
A roundup of biotech names with actions pending at the FDA in coming weeks.
By

Bret Jensen

 | Feb 7, 2018 | 1:00 PM EST
Achaogen, Taylor Morrison and Synchrony Financial are a part of my current shopping list.
By

Bret Jensen

 | Feb 5, 2018 | 1:00 PM EST
I believe the economy will be a bigger story than the market in 2018 and I doubt we will see the same gains for equities as we did in 2017.
By

Bret Jensen

 | Feb 2, 2018 | 1:00 PM EST
I hope we get a decent size market decline so I can add to some stakes in what I think are already undervalued biotech holdings.
By

Bret Jensen

 | Jan 31, 2018 | 11:30 AM EST
I added to two positions Tuesday, as growth catalysts are in play this earnings season.

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.